Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

TSX:CSCI - Post Discussion

COSCIENS Biopharma Inc > where the hell are the chewy bars?
View:
Post by lscfa on Aug 24, 2024 6:24pm

where the hell are the chewy bars?

mgmt, get on with it....

Feb 23, 2024 -
  • Chewable Oat Beta Glucan (OBG):

    • Ceapro’s team has successfully developed a unique, standardized formulation for a healthy confection which includes a high concentration of OBG with daily dosage according to approved claims in 10 developed countries.

    • Health Canada has approved Ceapro’s Novel Nutraceutical Product (NPN 80127493). The substantive claims derived from this approval include reduction of LDL cholesterol, supporting cardiovascular health reduction of Type 2 diabetes risks, source of fiber for the maintenance of general good health and support of a healthy digestive system.

    • Ceapro’s team anticipates the official commercial launch of its approved natural health product in H2, 2024, marking an important chapter in the Company's journey toward promoting wellness while expanding its business model. According to Future Market Insights, the oat beta-glucan market is expected to reach US$ 846.1 Million in 2032.

  •  
Comment by prophetoffactz on Aug 24, 2024 7:06pm
Latest financials: Oat Beta Glucan – Chewable for cholesterol reduction   Leveraging approved claims for the use of oat beta glucan as a proven cholesterol reduction ingredient in Canada, the United States of America and the European Union, and having received approval from Health Canada in December 2023, the Company has formulated a healthy edible product capable of delivering the ...more  
Comment by prophetoffactz on Aug 24, 2024 7:39pm
What is the "fulsome" update expected "shortly" going to include now that the merger is complete, the stock symbol and name changed, the new website is coming, and they are now on NASDAQ? Ronnie Miller says they are now optimized to bring "transformational" products to market. Draw us a complete picture for all programs. First avenanthramide results from the single ...more  
Comment by Hopeforthebest on Aug 25, 2024 10:56am
Well Iscfa, with this statement from proph "update expected "shortly" we know that this project is doom, add it to the list of failures by gagnon. Along with PGX commercial which proph admitted is a failure when he tried to compare gagnon to Thomas Edison (what a shameful attempt to justify gagnon's/his incompentence).
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities